<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852835</url>
  </required_header>
  <id_info>
    <org_study_id>8223</org_study_id>
    <nct_id>NCT04852835</nct_id>
  </id_info>
  <brief_title>COVID-19 Vaccine Response</brief_title>
  <acronym>COVACHUS</acronym>
  <official_title>Follow-up of COVID-19 Vaccine Response in Strasbourg University Hospitals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vaccination remains the main promising measure to fight against the COVID-19 pandemic. The&#xD;
      presumed efficacy of the vaccines is quite remarkable since it varies between 62 and 95%.&#xD;
      There is increasing evidence that sex-specific effects may lead to different outcomes of&#xD;
      vaccine safety and efficacy. However, sex-disaggregated data after COVID-19 vaccine are&#xD;
      lacking. The first purpose of the study is to determine antibody titers against SARS-CoV-2&#xD;
      spike after COVID-19 vaccination. The secondary purpose is to identify predictor factors of&#xD;
      immune response including age, gender and biological factors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">April 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 8, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of the relationship between the serological response to the COVID-19 vaccine and the demographic characteristics of the patient</measure>
    <time_frame>up to 1 month post-vaccination</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>COVID-19 Vaccines</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Any person, male or female, over 18 years of age who underwent vaccination and&#xD;
        anti-SARS-CoV-2 serological test after vaccination&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Any person, male or female, over 18 years of age who underwent vaccination and&#xD;
&#xD;
          -  anti-SARS-CoV-2 serological test after vaccination&#xD;
&#xD;
          -  having already given their consent for their biological resources to be:&#xD;
&#xD;
               -  stored in a biocollection of the Microbiology Technical Platform (PTM) having&#xD;
                  received an approval from the CPP Est-IV and declared to the Ministry of&#xD;
                  Education and Research under reference No. DC2009-1002;&#xD;
&#xD;
               -  subsequently reused, as well as the anonymized associated data, for research&#xD;
                  purposes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give clear information (person in an emergency, difficulty understanding&#xD;
             the subject, etc.)&#xD;
&#xD;
          -  Person under safeguard of justice&#xD;
&#xD;
          -  Person under guardianship or curatorship-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Service de Virologie - Hôpital Civil</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
    <phone>33.3.69.55.14.38</phone>
    <email>Samira.fafi-kremer@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Virologie - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
      <phone>33.3.69.55.14.38</phone>
      <email>Samira.fafi-kremer@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Samira FAFI-KREMER, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Josée Wendling, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélie Velay, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Floriane Gallais, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Gantner, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Morgane Solis, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie Laugel, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Humoral response</keyword>
  <keyword>Anti-spike antibodies</keyword>
  <keyword>Neutralizing antibodies</keyword>
  <keyword>Gender</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

